BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 30719448)

  • 1. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
    Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
    Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Chu H; Duan Y; Yang L; Schnabl B
    Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the gut microbiota in NAFLD.
    Leung C; Rivera L; Furness JB; Angus PW
    Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease.
    Mouzaki M; Bandsma R
    Curr Drug Targets; 2015; 16(12):1324-31. PubMed ID: 25882223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
    de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
    Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver and the gut microbiota.
    Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E
    Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
    Bakhshimoghaddam F; Alizadeh M
    Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiome and nonalcoholic fatty liver diseases.
    Zhu L; Baker RD; Baker SS
    Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
    Jiao N; Baker SS; Chapa-Rodriguez A; Liu W; Nugent CA; Tsompana M; Mastrandrea L; Buck MJ; Baker RD; Genco RJ; Zhu R; Zhu L
    Gut; 2018 Oct; 67(10):1881-1891. PubMed ID: 28774887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbial metabolites in non-alcoholic fatty liver disease.
    Zhou D; Fan JG
    World J Gastroenterol; 2019 May; 25(17):2019-2028. PubMed ID: 31114130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
    Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
    Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites.
    Ding Y; Yanagi K; Cheng C; Alaniz RC; Lee K; Jayaraman A
    Pharmacol Res; 2019 Mar; 141():521-529. PubMed ID: 30660825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
    World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.